Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?

Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent

More from Archive

More from Pink Sheet